ClinConnect ClinConnect Logo
Search / Trial NCT05929937

No Opioids vs. Minimal Opioids Following Inguinal Hernia Repair

Launched by CLAYTON PETRO · Jul 1, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying pain management after a common surgery called inguinal hernia repair. Researchers want to find out if patients can manage their pain without taking opioids, which are strong pain medications that can be addictive. Specifically, they are comparing two groups: one group will receive no opioids after surgery, while the other group will receive a small amount of opioids. The goal is to see if those who don’t take opioids will need fewer refills for pain medication and if their quality of life after surgery is similar to those who do take opioids.

To be eligible for this trial, participants must be at least 18 years old and scheduled for an elective inguinal hernia repair surgery. They should be able to tolerate general anesthesia, which is a type of medication used to keep patients asleep during surgery. However, people who have chronic pain and are taking opioids regularly, or those who cannot handle general anesthesia or pain medications, will not be included. If you choose to participate, you will be monitored for 30 days after your surgery to assess your pain levels and overall recovery. This trial aims to find safer pain management options for patients after surgery.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adult patients aged 18 years or older
  • Patients undergoing elective unilateral or bilateral inguinal hernia repairs
  • Patients able to tolerate general anesthesia
  • Exclusion Criteria:
  • Patients who cannot tolerate general anesthesia,
  • Patients who cannot tolerate opioids or NSAIDS,
  • Patients on opioids for chronic pain management (defined as near daily use within 90 days),
  • Patients who undergo surgeries requiring extensive dissection/hernia sac reduction, or additional procedures,
  • Patients requiring inpatient admission postoperatively
  • Patients who are not able to understand and sign a written consent form

About Clayton Petro

Clayton Petro is a leading clinical trial sponsor dedicated to advancing medical research and innovation through the development of novel therapies. With a strong focus on improving patient outcomes, Clayton Petro collaborates with healthcare professionals, regulatory bodies, and research institutions to design and execute high-quality clinical trials across various therapeutic areas. Their commitment to ethical practices and rigorous scientific standards ensures the integrity of their research, while their experienced team of professionals works diligently to bring groundbreaking treatments to market, ultimately enhancing the quality of care for patients worldwide.

Locations

Milwaukee, Wisconsin, United States

Knoxville, Tennessee, United States

Cleveland, Ohio, United States

Cleveland, Ohio, United States

Fountain Valley, California, United States

Royal Oak, Michigan, United States

Patients applied

0 patients applied

Trial Officials

Clayton C Petro, MD

Principal Investigator

The Cleveland Clinic

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported